ZA89813B - Method for treating renal diseases - Google Patents

Method for treating renal diseases

Info

Publication number
ZA89813B
ZA89813B ZA89813A ZA89813A ZA89813B ZA 89813 B ZA89813 B ZA 89813B ZA 89813 A ZA89813 A ZA 89813A ZA 89813 A ZA89813 A ZA 89813A ZA 89813 B ZA89813 B ZA 89813B
Authority
ZA
South Africa
Prior art keywords
renal diseases
treating renal
igf
treatment
renal
Prior art date
Application number
ZA89813A
Other languages
English (en)
Inventor
Ernst Rudolf Froesch
Rudolf Froesch Ernst
Juergen Zapf
Zapf Juergen
Hans-Peter Guler
Guler Hans-Peter
Christoph Schmid
Schmid Christoph
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of ZA89813B publication Critical patent/ZA89813B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
ZA89813A 1988-02-05 1989-02-02 Method for treating renal diseases ZA89813B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88810071 1988-02-05

Publications (1)

Publication Number Publication Date
ZA89813B true ZA89813B (en) 1989-09-27

Family

ID=8200570

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA89813A ZA89813B (en) 1988-02-05 1989-02-02 Method for treating renal diseases

Country Status (10)

Country Link
US (1) US5106832A (ja)
EP (1) EP0327503B1 (ja)
JP (1) JP2783825B2 (ja)
KR (1) KR0131088B1 (ja)
AT (1) ATE86496T1 (ja)
AU (1) AU621583B2 (ja)
CA (1) CA1336400C (ja)
DE (1) DE68905203T2 (ja)
DK (1) DK169232B1 (ja)
ZA (1) ZA89813B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
CA2109820A1 (en) * 1992-03-24 1993-09-30 George N. Cox Refolding and purification of insulin-like growth factor i
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
EP0732933B1 (en) * 1993-11-15 2002-10-09 Celtrix Pharmaceuticals, Inc. Use of igf-1 and igfbp-3 in the manufacture of a medicament for treating a renal disorder
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5837675A (en) * 1995-02-03 1998-11-17 Brox; Alan G. Synergistic effect of insulin-like growth factor-I and erythropoietin
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
JPH0995455A (ja) * 1995-09-29 1997-04-08 Sumitomo Pharmaceut Co Ltd 腎機能改善剤
AU4196697A (en) * 1996-09-16 1998-04-14 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US7074762B2 (en) * 1998-01-05 2006-07-11 Washington University Composition and method for improving function of embryonic kidney transplants
AU762047B2 (en) * 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
HUP0500733A3 (en) * 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
JP2004536069A (ja) 2001-05-24 2004-12-02 ニューロンズ・リミテッド Ｇｐｅ類縁体及びペプチドミメティック
EP1791551B1 (en) * 2004-08-30 2020-02-26 Ipsen Biopharmaceuticals, Inc. Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.

Also Published As

Publication number Publication date
DK169232B1 (da) 1994-09-19
JP2783825B2 (ja) 1998-08-06
EP0327503B1 (en) 1993-03-10
AU2899889A (en) 1989-08-10
DK52089A (da) 1989-08-06
US5106832A (en) 1992-04-21
KR890012666A (ko) 1989-09-18
AU621583B2 (en) 1992-03-19
CA1336400C (en) 1995-07-25
DE68905203T2 (de) 1993-07-22
DK52089D0 (da) 1989-02-03
DE68905203D1 (de) 1993-04-15
EP0327503A1 (en) 1989-08-09
ATE86496T1 (de) 1993-03-15
KR0131088B1 (ko) 1998-04-17
JPH01226827A (ja) 1989-09-11

Similar Documents

Publication Publication Date Title
ZA89813B (en) Method for treating renal diseases
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
HUT65754A (en) Process for production of preparations containing complement inhibitors for treatment of inflammatory intestinal-and dermal-diseases
EP0787802A3 (ja)
HK15293A (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
HU895785D0 (en) Process for the preparation of compositions and medical preparations containing acid-resistent fibroplast growth activator for treating gastrointestinal ulcer
AU5051693A (en) Method and composition for treating inflammatory bowel disorders
AU693833B2 (en) Products containing G-CSF and TNF binding protein
EP0661990A4 (en) METHOD FOR THE TREATMENT OF CATABOLIC CONDITIONS AND SYSTEMIC TISSUE LESIONS.
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
AU582972B2 (en) Lipoprotein adsorbent for use in extracorporeal circulation treatment and process for preparing thereof
EP0324802A4 (en) Method for the treatment of body tissues and the administration of drugs thereto
ZA894945B (en) Strontium salt,process for the preparation thereof and pharmaceutical compositions containing it
EP0158880A3 (en) Liposomes with inhalable allergens for treatment of allergies, method for their preparation and pharmaceutical compositions containing them
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
AU1071888A (en) Pharmaceutical preparation for treatment of hyperacidity in body fluids
PL271057A1 (en) Method of making therapeutic cream for treatment of dermatopathies, in particular burns
PL277468A1 (en) Apparatus for surgical treatment of astigmatism
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
AU575849B2 (en) Pharmaceutical composition and method for treatment of psychomotor excitement
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein
BG47669A1 (en) Method for treating of carcinome located in proximal part of lower third of rectum
ZA888338B (en) Pharmaceutical compositions and method of treatment
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози